Location
Moultrie, GA
Start Date
17-4-2026 12:00 PM
End Date
17-4-2026 1:00 PM
Description
Introduction: Stimulant medications are first-line therapy for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Because these agents increase sympathetic activity, concerns persist regarding their cardiovascular safety, including arrhythmias and sudden cardiac death (SCD). Debate continues regarding whether routine electrocardiogram (ECG) screening prior to stimulant initiation reduces the risk of serious cardiac events. Divergent recommendations from professional organizations have generated ongoing uncertainty about the balance between precaution and evidence-based practice. Our objective is to critically evaluate the literature of cardiovascular effects of stimulant therapy in children and adolescents and to assess whether routine cardiovascular monitoring, including universal ECG screening, improves clinical outcomes.
Methods: A narrative review of peer-reviewed studies and consensus statements was conducted. Studies were included if they examined pediatric patients receiving ADHD pharmacotherapy and reported cardiovascular measures, arrhythmia incidence, ECG findings, or SCD outcomes. Evidence was synthesized qualitatively with emphasis on clinical relevance and screening impact.
Results: Stimulant therapy is associated with modest increases in systolic blood pressure, diastolic blood pressure, and heart rate. These changes generally remain in the normal physiologic ranges and have not been linked to sustained cardiovascular morbidity in otherwise healthy children and adolescents. Available data does not demonstrate an increase in incidence of SCD among stimulant users compared with baseline pediatric rates. Routine ECG screening in asymptomatic patients yields low rates of actionable findings and has not been shown to reduce adverse cardiovascular outcomes.
Discussion: The existing literature affirms that careful cardiovascular history taking, physical examination, and routine blood pressure and heart rate monitoring prior to initiating stimulations in pediatric patients. Universal ECG screening in low-risk pediatric populations is not supported by outcome data. A risk-stratified approach remains the most evidence-aligned and clinically responsible strategy.
Embargo Period
5-27-2026
Included in
Routine or Reassurance: Cardiovascular Monitoring in Children Receiving ADHD Medications
Moultrie, GA
Introduction: Stimulant medications are first-line therapy for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Because these agents increase sympathetic activity, concerns persist regarding their cardiovascular safety, including arrhythmias and sudden cardiac death (SCD). Debate continues regarding whether routine electrocardiogram (ECG) screening prior to stimulant initiation reduces the risk of serious cardiac events. Divergent recommendations from professional organizations have generated ongoing uncertainty about the balance between precaution and evidence-based practice. Our objective is to critically evaluate the literature of cardiovascular effects of stimulant therapy in children and adolescents and to assess whether routine cardiovascular monitoring, including universal ECG screening, improves clinical outcomes.
Methods: A narrative review of peer-reviewed studies and consensus statements was conducted. Studies were included if they examined pediatric patients receiving ADHD pharmacotherapy and reported cardiovascular measures, arrhythmia incidence, ECG findings, or SCD outcomes. Evidence was synthesized qualitatively with emphasis on clinical relevance and screening impact.
Results: Stimulant therapy is associated with modest increases in systolic blood pressure, diastolic blood pressure, and heart rate. These changes generally remain in the normal physiologic ranges and have not been linked to sustained cardiovascular morbidity in otherwise healthy children and adolescents. Available data does not demonstrate an increase in incidence of SCD among stimulant users compared with baseline pediatric rates. Routine ECG screening in asymptomatic patients yields low rates of actionable findings and has not been shown to reduce adverse cardiovascular outcomes.
Discussion: The existing literature affirms that careful cardiovascular history taking, physical examination, and routine blood pressure and heart rate monitoring prior to initiating stimulations in pediatric patients. Universal ECG screening in low-risk pediatric populations is not supported by outcome data. A risk-stratified approach remains the most evidence-aligned and clinically responsible strategy.
Comments
Presented by Alexandra Ortiz.